Kidney cancer advocate involved in Patient 2.0 and Health 2.0 communities.
Washington, DC
Joined February 2010
- Tweets1.1K
- Following678
- Followers983
- Likes2.1K
Dena Battle retweeted
Promotion to Professor — an accomplishment I have worked for over many years, effective today. Thanks @suzanneconzenmd @carlosarteagamd & all colleagues around the world who wrote/called for me. Grateful beyond words. @drchoueiri @montypal @albigesL @ERPlimackMD @Daniel_J_George
Dena Battle retweeted
Thanks for sharing. Proud to finally show data to support the practice we have followed for a long time. @SUO_YUO fellow @HFu_MD put this together. Even when surgery is the the next step, my first ? is what life events do you have coming up - weddings, trips, etc. SRMs ≠ emergencies.
@EurUrolOncol
#kidneycancer ≠ automatic surgery
25-y prospective data from NCI @markballmd supports 3cm rule in bilat multifoc papillaryRCC
excellent onc outcomes & minimized cumulative harms of repeat tx
long-term natural-hist data to refine ##activesurveillance
sciencedirect.com/science/ar…
Dena Battle retweeted
QOL endpoints are critical. But name studies in which the usual cancer endpoints were negative but QOL was positive! Unless we create better ways to measure QOL we will continue to have a problem. With multiple sequential effective (sometimes toxic) therapies this is critical
85% planned it. Only 47.5% reported it.
In our new study of 80 phase III #GUOnc trials, QoL endpoints were frequently prespecified but often went unreported.
Among trials that prespecified QoL, reporting was significantly more common when the primary endpoint was positive: 71% vs 31%.
Our findings highlight the need for consistent, transparent reporting of patient-centered outcomes — regardless of trial outcome.
Now published open access in @JCOOA_ASCO :
ascopubs.org/doi/10.1200/OA-…
#Medtwitter #Onctwitter #Gusm
@OncoAlert
Thank you to the amazing partners on this project! @TiansterZhang @DrVaishampayan @lisapic @AlbigesL @MichaelStaehler @spsutkaMD @d_shapiro1 @uretericbud @Cold_Steel_1970. And thanks to @OncoAlert for highlighting! Let’s talk about cure in #kidneycancer!
DAY Two of OncoAlert 🚨 Coverage of #IKCSEU26
Provider Perceptions of Cure in Renal Cell Cancer Presented by Ms. Dena Battle🇺🇸 of @kcCURE
RCC specialists demonstrate notable hesitancy in using the term “cure,” even in clinical contexts where long-term outcomes may justify it. This reluctance reflects not only clinical uncertainty but also parallels similar reservations among patients. The absence of a standardized definition contributes to inconsistent communication, potentially affecting expectations and decision-making. Establishing clearer, consensus-driven terminology around “cure” in RCC could enhance transparency, improve physician–patient alignment, and support more informed shared decision-making. Addressing this linguistic and conceptual gap may ultimately strengthen trust and facilitate more meaningful discussions about prognosis and treatment goals in renal cell carcinoma care. #KidneyCancer
@KidneyCancer Jean-Christophe Bernhard @univbordeaux @AlbigesL @gustaveroussy @TiansterZhang @Dr_SabyGeorge @ZakhariaYousef @ERPlimackMD @Ric_Campi @DrIacovelli @RebuzziSara @weoncologists @GEVaughan1 @salvolarosa @DrYukselUrun #KidneyCancer @daniyal_jafree @EJonasch @IKCCorg @sophiemerrick1 @BarbaraJereczek @ESTRO_RT @ZakhariaYousef @kuraoncology @Selcuk__Erdem @drulkav @RCCadvocate
Dena Battle retweeted
DAY Two of OncoAlert 🚨 Coverage of #IKCSEU26
Provider Perceptions of Cure in Renal Cell Cancer Presented by Ms. Dena Battle🇺🇸 of @kcCURE
RCC specialists demonstrate notable hesitancy in using the term “cure,” even in clinical contexts where long-term outcomes may justify it. This reluctance reflects not only clinical uncertainty but also parallels similar reservations among patients. The absence of a standardized definition contributes to inconsistent communication, potentially affecting expectations and decision-making. Establishing clearer, consensus-driven terminology around “cure” in RCC could enhance transparency, improve physician–patient alignment, and support more informed shared decision-making. Addressing this linguistic and conceptual gap may ultimately strengthen trust and facilitate more meaningful discussions about prognosis and treatment goals in renal cell carcinoma care. #KidneyCancer
@KidneyCancer Jean-Christophe Bernhard @univbordeaux @AlbigesL @gustaveroussy @TiansterZhang @Dr_SabyGeorge @ZakhariaYousef @ERPlimackMD @Ric_Campi @DrIacovelli @RebuzziSara @weoncologists @GEVaughan1 @salvolarosa @DrYukselUrun #KidneyCancer @daniyal_jafree @EJonasch @IKCCorg @sophiemerrick1 @BarbaraJereczek @ESTRO_RT @ZakhariaYousef @kuraoncology @Selcuk__Erdem @drulkav @RCCadvocate
Dena Battle retweeted
🚨Reminder🚨 Join us tomorrow at 9am for 'Advancing Care in #KidneyCancer: From Diagnosis to Survivorship,' hosted by @BraunMDPhD
➡️Agenda: bit.ly/4t1t5fZ
➡️RSVP: bit.ly/3OkdSqO
@YaleCancer @cure_today @kcCURE @RCCadvocate
Dena Battle retweeted
Doctors! Tell us YOUR answer! How should the term “cure” be used in #kidneycancer? #ESMO25 Let’s see how many responses we can get! @DrChoueiri @montypal @DrYukselUrun @TiansterZhang @Uromigos @OncoAlert surveymonkey.com/r/MDCure
#ESMO25 starts today! Excited to present #evidencebased data from @kcCURE exploring how metastatic #kidneycancer pts interpret the word “cure.”
Dena Battle retweeted
Every patient is first a human being with a name, a story, a dream.
Dignity is part of the treatment.
Never reduce a life to a diagnosis…
Dena Battle retweeted
🎉 Congratulations @ejasonabel who will receive the KCA's Andrew C. Novick Award at #IKCSNA25! This award recognizes excellence in #kidneycancer urology care.
Read more: kidneycancer.org/2025-ikcsna…
Dena Battle retweeted
Supported by @DOD #KCRP Idea Development Award. We are grateful for the funding & the chance to make a difference for our patients w/ #kidneycancer. For more details please see our paper #MolecularCancer @BioMedCentral. molecular-cancer.biomedcentr… #FIN
Dena Battle retweeted
Last week @andyzwang & I published 1st of our translational research in #MolecularCancer @BioMedCentral, developing a multifunctional immunotherapy nanoparticle (MINP) to treat #kidneycancer. Thanks to #KinmanAu & #SiqingLi, 2 of our postdocs @utswcancer who did the work. 1/n
Dena Battle retweeted
📣 Live at #ASCO25: Learn from real-world #RCC cases with @montypal, Dr. McDermott & @TiansterZhang
✅ IO-based regimens
✅ Sequencing therapies
✅ Shared decision-making
🗓️ May 31 | 7:00 PM CDT
🔗 bit.ly/RCC-T
Dena Battle retweeted
#ScientificTourDeForce and a brilliant demonstration of how much we can learn from outlier events and rare disease. #RMC The matrix of factors that impact immune function are vast, but not impenetrable, and offers avenues for immune based prevention. #WorthTheRead
1/5 People living with sickle-cell disease (SCD) face ↑ cancer risk, including #RenalMedullaryCarcinoma. Our latest @ImmunityCP study suggests a culprit is the reshaping CD8⁺ T cell chromatin by SCD 👉authors.elsevier.com/sd/arti… #MsaouelLab
Dena Battle retweeted
Amsterdam • Keukenhof tulips, windmills, canals, and best of all, friends. Nothing better than getting to see great friends all together overseas. Missed being with everyone #IKCSEU25 but enjoyed dinner @TiansterZhang @RCCadvocate @MichaelStaehler
So proud of @MichaelStaehler for this well deserved honor. Your relentless commitment to improving patient care inspires me every day. 🧡
🎉CONGRATULATIONS to @MichaelStaehler, recipient of the KCA's 2025 John Fitzpatrick Award recognizing excellence in urology care! The award will be presented at #IKCSEU25, don't miss his lecture! kidneycancer.swoogo.com/IKCS…
70% of health-related internet searches are zero-click - which means pts are relying on snippets and AI overviews for information. When you see something like this that is outdated, misleading, or both - click on the feedback button. It's a small way you can help improve information for #kidneycancer patients.
Dena Battle retweeted
Exploring the burden of cancer in metastatic renal cell carcinoma (mRCC) 📊🧬 This study sheds light on the impact of mRCC on patients & healthcare systems. Don’t miss these key insights @ASCO #GU25! @RCCadvocate @kcCURE
Dena Battle retweeted
Clear cell RCC is heterogeneous. @utswcancer’s @TiansterZhang presents the new frontier and dares us to imagine patients unique disease treated uniquely. #GU25 #kidneycancer #diseaseburdenzero
Dena Battle retweeted
Great Poster by our friends at @kcCURE at #GU25 Spoke to First Author Dena Blattle @RCCadvocate who tells us more:
Disease Burden in mRCC
#kidneycancer pts spend HOURS⏳ thinking about #cancer. In last 9⃣0⃣ days, 36% have gone to ER. >1/3 of patients say that cancer always/often impacts their ability to eat, sleep and engage with family and friends. Surviving is not the same as living. #diseaseburdenzero
Meghan Griffith
@PavlosMsaouel
@spsutkaMD
@DrVaishampayan
@TiansterZhang
@MichaelStaehler
Ping
@NazliDizman @ziremozay @Chrislabaki1 @DRBakaloudiMD @nsayeghmd @seanmmcbride @scserendipity1 @ReneeSaliby @MikeSerzanMD
@montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen
@EfstathiouEleni @tompowles1 @BraunMDPhD @cdanicas @DrYukselUrun
@nataliagandur @acampsmalea @BiagioRicciutMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Dr_Ivanoncologo @Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK